聚乙二醇化重组人粒细胞集落刺激因子在化疗后中性粒细胞减少症中的临床应用价值

Clinical application value of pegylated recombinant human granulocyte-colony stimulating factor in neutropenia after chemotherapy

恶性肿瘤患者化疗过程中,中性粒细胞减少症是骨髓抑制性化疗药物引起的最主要不良事件,其减少程度和持续时间与患者感染风险甚至死亡风险密切相关。粒细胞集落刺激因子(granulocyte-colony stimulating factor,G-CSF)是一种内源性造血生长因子,可刺激中性粒细胞前体的增殖和分化,并增加成熟中性粒细胞的存活率和活性。重组人粒细胞集落刺激因子(recombinant human granulocyte-colony stimulating factor,rhG-CSF)是一种人工合成的具有G-CSF生物活性的细胞因子,临床用于细胞毒类化疗药物治疗后出现的中性粒细胞减少症的预防和治疗,但其半衰期短,应用过程中需多次用药,反复注射。聚乙二醇化重组人粒细胞集落刺激因子(pegylated recombinant human granulocyte-colony stimulating factor,PEG-rhG-CSF)是其长效剂型,患者化疗每周期仅需1次给药,因其稳定、方便的优点已广泛应用于临床。本文对PEG-rhG-CSF在化疗后中性粒细胞减少症中的临床应用价值作一综述,旨在为其进一步临床应用提供参考。

During chemotherapy of malignant tumors,neutropenia is the most important adverse event caused by myelosuppressive chemotherapeutics,of which the degree and duration are closely related to the risk of infection and even death.Granulocyte-colony stimulating factor(G-CSF) is an endogenous hematopoietic growth factor that can stimulate the proliferation and differentiation of neutrophil precursors,and increase the survival rate and activity of mature neutrophils.Recombinant human granulocyte-colony stimulating factor(rhG-CSF) is an artificially synthesized cytokine with G-CSF biological activity.It is used clinically for the prevention and treatment of neutropenia after treatment with cytotoxic chemotherapeutics,requiring multiple medications and repeated injections during application for its short half-life.Pegylated recombinant human granulocyte-colony stimulating factor(PEG-rhG-CSF) is its long-acting dosage form,and patients only need to be administered once per cycle of chemotherapy,which has been widely used in clinical practice because of its stability and convenience.This paper systematically described the clinical application value of PEG-rhG-CSF in neutropenia after chemotherapy,aiming to provide a reference for its further clinical application.